Recent advances in DNA sequencing techniques have led to an increase in the identification of single nucleotide polymorphisms (SNPs) in BRCA1 and BRCA2 genes, but no further information regarding the deleterious probability of many of them is available (Variants of Unknown Significance/VUS). As a result, in the current study, different sequence- and structure-based computation...

Breast carcinoma is one of the most common tumors in women. The immune microenvironment, especially T cell infiltration, related to occurrence and prognosis breast carcinoma. This study investigated gene expression patterns associated with tumor-infiltrating CD4+ CD8+ cells invasive carcinomas. data corresponding clinical phenotype from Cancer Genome Atlas Invasive Carcinoma (TCGA-BRCA) were do...

Although breast cancer (BrCa) may be detected at an early stage, there is a shortage of markers that predict tumor aggressiveness and a lack of targeted therapies. Histone chaperone FACT, expressed in a limited number of normal cells, is overexpressed in different types of cancer, including BrCa. Recently, we found that FACT expression in BrCa correlates with markers of aggressive BrCa, which p...

Metastatic breast cancer (BrCa) is still one of the main causes of cancer death in women. Metabolic syndrome (MeS), a risk factor for BrCa, is associated to high grade tumors, increased metastasis and recurrence of this disease. C-terminal binding protein 1 (CTBP1) is a co-repressor of tumor suppressor genes that is activated by low NAD+/NADH ratio. Previously, we demonstrated that CTBP1 hypera...

HYPOTHESIS The DNA base pair sequence in all humans is 99.6% identical and Epigenetic factors influence substantively the RNA processing and translational requisition of the initial DNA message and There are thousands of sequence variants of the BRCA1 and BRCA 2 genes and Family history always trumps BRCA 1 and 2 status so For screening and therapeutic purposes, BRCA 1 and BRCA 2 genetic testin...

DESCRIPTION Update of the 2005 U.S. Preventive Services Task Force (USPSTF) recommendation on genetic risk assessment and BRCA mutation testing for breast and ovarian cancer susceptibility. METHODS The USPSTF reviewed the evidence on risk assessment,genetic counseling, and genetic testing for potentially harmful BRCA mutations in asymptomatic women with a family history of breast or ovarian c...

Abstract Over the years, attention towards role of phytochemicals in dietary natural products reducing risk developing cancer is rising. Cancer second primary cause mortality worldwide. The current therapeutic options for treatment are surgical excision, immunotherapy, chemotherapy, and radiotherapy. Unfortunately, case metastases or chemoresistance, become very limited. Despite advances medica...

male breast cancer is a rare disease with an increasing trend. due to limited information especially about the genetic basis of the disease in iran and the lower age of its onset, the disease requires more attention. the aim of this study was to screen the male patients with breast cancer for brca mutations as well as tissue markers of estrogen receptor (er), progesterone receptor (pr), human e...

Hereditary breast cancer comprises 10% of all breast cancers. The most prevalent genes causing this pathology are BRCA1 and BRCA2 (breast cancer early onset 1 and 2), which also predispose to other cancers. Despite the outstanding relevance of genetic screening of BRCA deleterious variants in patients with a history of familial cancer, this practice is not common in Latin American public instit...

The breast cancer susceptibility genes 1 (BRCA1) and 2 (BRCA2) are cellular proteins involved in DNA repair. They are normally expressed in the breast, ovaries, prostate, and other tissues. Their germline mutation is the cause of hereditary breast-ovarian cancer syndromes. BRCA mutation carriers are also susceptible to other cancers, notably prostate cancer. In this article, we review the role ...